Showing 1894 results
June 2016
-
Story Discovery
Cancer researchers ready to aim for cures
New head of oncology research hopes to build on recent advances, explore new therapeutic approaches and beat certain cancers for good.
-
Story Discovery
Confidence led this researcher to swim against the current
A researcher reflects on her successful journey from Venezuela to the US in which she became a doctor, a scientist, and a mother.
-
Press release
New data demonstrates Sandoz' etanercept and rituximab biosimilar candidates bioequivalent to originator products
Sandoz' biosimilar etanercept candidate shows pharmacokinetic (PK) bioequivalence with no clinically meaningful differences in safety, tolerability and immunogenicity to the originator.[1] … -
Press release
Novartis announces AMG 334 significantly reduces patients' monthly migraine days in phase II study of chronic migraine prevention
Phase II 20120295 study of AMG 334 met primary endpoint, confirming efficacy and safety in patients with chronic migraine over 12 weeks of treatment Migraine is a leading cause of disability,… -
Story Patient Perspectives
The future of chronic myeloid leukemia is evolving
-
Press release
Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016
Up to 80% of ankylosing spondylitis and 84% of psoriatic arthritis patients treated with Cosentyx® at two years had no radiographic progression in the spine or joints, respectively[1],[2] … -
Story Discovery
The eye: the fastest muscle in the human body
How much do you know about eyes? Learn more about the fastest muscle in the human body.
-
Press release
Novartis combination therapy Tafinlar® + Mekinist® demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma
Study is longest Ph III survival follow-up to date of BRAF V600E/K mutation-positive melanoma patients who received a targeted combination therapy Latest data show an estimated 44% of… -
Press release
Novartis pivotal data for Tafinlar® + Mekinist® demonstrated a 63 percent overall response rate in treating rare form of lung cancer
The median Duration of Response for BRAF V600E-mutant NSCLC patients treated with Tafinlar® + Mekinist® combination therapy was 9 months Efficacy analyses also presented for INC280 (… -
Story Access to Healthcare
Fighting pneumonia, the biggest killer of young children
Pneumonia causes around 2 million child deaths per year globally and the burden is especially heavy in a country like Bangladesh, where a third of the population is aged 14 or below.
-
Story Patient Perspectives
Lung Cancer: To test or not to test
For patients with lung cancer, biomarker testing may be an option.
-
Press release
Novartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission (TFR) after stopping Tasigna®
In ENESTfreedom, 51.6% of eligible first-line Tasigna patients maintained TFR for 48 weeks after stopping treatment; study did not meet its statistical primary endpoint, specifically the >…